ArticleScientific reports2025
Long term effectiveness of intraoperative radiotherapy given as a boost in adjuvant treatment for oral cavity cancers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral cancer treatment of choice is surgical excision with an organ preservation, if it is possible. Radiation therapy is commonly used as a postoperative treatment. Delivering radiation dose during surgery, defined as intraoperative radiotherapy (IORT), can be very useful especially in case of high risk of recurrence or where gross or macroscopic residual disease are present. The aim of this retrospective study is to evaluate the effectiveness of IORT combined with postoperative fractionated irradiation (EBRT) of patients with squamous cell carcinoma of the oral cavity. The study included 23 patients: IORT dose of 5-7.5 Gy was delivered using 50 kV X-rays generated by INTRABEAM™, combined with EBRT of 50-60 Gy in 25-30 fractions depending on presence of extracapsular invasion and narrow or positive surgical margins. Standard statistical tests were used. Median follow up was 64 months (range 8-222 months). The 5-year local tumour control was 92% and 82.5% in the 10-year follow-up. The 5-year overall survival (OS) was 56% and decreased to 45% during the next 5 years. There were no differences in the LTC, DFS and OS regarding sex, T-stage, grade and tumour localization, although a small group of analysed cases may raise some uncertainties. Acute side effects of combined IORT and EBRT were mild and no late complications occurred. The present study indicated that low-energy X-rays IORT combined with postoperative EBRT is a feasible and safe therapeutic modality which likely reduces a risk of locoregional recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.